The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition

19 Oct 2011 • by Natalie Aster

New YorkSmall tumors are easier to eradicate because rates of cell division are generally faster. To affect a cure, the stem cells that give rise to clones of malignant cells must be destroyed. Unfortunately, stem cells do not divide as rapidly as other tumor cells. Resection or irradiation to reduce tumor size may prompt the stem cells to divide, thus making them more susceptible to chemotherapy. Tumor cells with mutations of the P53 gene may be resistant to chemotherapeutic agents that work by damaging DNA, so other drugs may be more effective.

Chemotherapeutic agents are not selective for tumor cells, and a certain amount of normal cell death also occurs. Rapidly dividing cells, particularly those of the bone marrow, intestinal epithelia, and hair follicles, are most affected. Bone marrow depression is a most serious side effect as it predisposes the patient to anemia, bleeding and infection.

New approaches to cancer drug therapy have emerged that indirectly inhibit tumors rather than seeking to kill tumor cells directly. A promising approach is to interrupt the tumor’s blood supply by a progressively expanding network of capillaries. The development of new capillaries, called angiogenesis, is accomplished by migration and growth of endothelial cells. Drugs that block angiogenesis have been shown to shrink tumors dramatically in animal models with virtually no side effect.

Report Details:

The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition

Published: October 2011
Pages: 245
Price: US$ 3,500.00

Report Sample Abstract

Hormone Therapy: At A Glance

A substantial body of evidence indicates that hormones play an auxiliary role in neoplastic transformation. One idea is that excessive hormonal stimulation of the target organ increases the number of cell divisions; random genetic errors accumulate during the repeated cell division and can lead to neoplastic phenotypes. Cancers of hormone-responsive tissues account for more than XX% of newly diagnosed cancers in the United States. In prostate carcinoma, the goal is to remove androgen stimulation and in breast carcinoma, estrogen stimulation. These therapies will be effective only if the tumor cells contain the corresponding steroid hormone receptor.

The development of the field of hormonal control of cancer is largely due to the work of Charles B. Huggins. Huggins shared the Nobel Prize in medicine with Peyton Rous in 1966. Prostatic cancer commonly spreads to the skeleton, and the morbidity of skeletal pain can be incapacitating. Localized prostate cancer is treated with surgery or irradiation. Metastatic prostate cancer is treated by eliminating androgens.

More information can be found in the report “The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition” by Kalorama Information.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970